3 Australian Growth Stocks To Own In November 2026

Australian inflation data is under fresh scrutiny after questions about whether official CPI figures might be overstating price pressures and keeping interest rates higher for longer. Higher borrowing costs can punish weaker operators and reward businesses with healthy cash reserves and room to grow. This article highlights three Australian high growth potential stocks from our screener that analysts think combine strong growth prospects with balance sheets built to handle that pressure.

The stocks covered below are just a small sample, and the full high growth potential screen surfaced 32 more Australian companies with equally compelling stories that are not detailed here. If you want to move faster, head straight to the Best high growth potential screener to identify, compare, and analyze the ideas that best fit your own portfolio focus.

Ramelius Resources (ASX:RMS)

Overview: Ramelius Resources is an Australian gold producer built around its Mt Magnet mining hub, where current output and nearby deposits are central to its operations.

Operations: Ramelius generated A$1.03b of revenue from its Mt Magnet segment, highlighting how heavily its business leans on that single producing hub.

Market Cap: A$6.46b

Ramelius Resources matters for this high growth potential theme because Mt Magnet already delivers meaningful production while funding an expansion pipeline that could alter the company’s earnings profile if executed well.

"Ramelius maintains very low debt levels and a substantial pipeline of projects."

A key consideration is how one unresolved cost pressure around that growth pipeline may influence future margins and the value of every additional ounce produced.

That pressure point is exactly why the full narrative for Ramelius Resources digs into how Ramelius Resources could balance growth, capital intensity, and any margin squeeze if conditions stay tight.

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals is a biopharmaceutical company developing DAYBUE for Rett syndrome and Fragile X, with NNZ-2591 targeting several rare neurological disorders.

Operations: Neuren generated A$69.5 million from commercial products, entirely from the United States, reflecting early revenue concentration in DAYBUE.

Market Cap: A$2.6b

Neuren Pharmaceuticals fits this high growth potential theme because DAYBUE is already commercial, NNZ-2591 extends the opportunity set, and the balance sheet is positioned to support that expansion.

"The expectation of increased diagnosed population and patient uptake of DAYBUE in the U.S. indicates potential revenue growth with more patients getting access to the drug."

The real swing factor is how management handles one emerging pressure around future profitability as DAYBUE matures and the pipeline advances.

That profitability question is exactly where Neuren Pharmaceuticals gets interesting. The full narrative for Neuren Pharmaceuticals unpacks how DAYBUE momentum and the NNZ-2591 pipeline could reshape the earnings mix.

Lynas Rare Earths (ASX:LYC)

Overview: Lynas Rare Earths mines and processes rare earth materials, supplying key magnet metals that feed into clean energy and electrification supply chains.

Operations: Lynas generated A$977.9 million from its Rare Earth Operations segment, reflecting a focused revenue base in mined and processed rare earth products.

Market Cap: A$12.2b

Lynas Rare Earths is connected to this high growth potential theme because its Mt Weld ore body and processing hubs are closely linked to demand for rare earth magnets in electric vehicles and wind turbines, which ties earnings forecasts directly to the clean-energy build out.

"Advancing the acquisition of the Caldeira ionic clay project in Brazil, which roughly doubles the mineral resource base and adds significant NdPr and DyTb feedstock, positions Lynas Rare Earths to increase future ex China supply of both light and heavy rare earths."

What happens to that growth story if one major cost or regulatory pressure unexpectedly squeezes the rare earth margin profile?

If that cost or regulatory shock hits, the full narrative for Lynas Rare Earths shows how Lynas Rare Earths could still accelerate value by relying on its broader resource base and customer mix.

Seeking Alternatives Before The Crowd

Fresh ideas move first. By the time every investor sees the breakout, early momentum can be gone and prices already flying. Scan these curated lists while it matters to consider potential opportunities earlier.

• Look for off-the-radar growth stories with comparatively cleaner balance sheets using a curated 15 high quality undiscovered gems that are still under the radar for now.
• Focus on potential compounding candidates through a curated 6 resilient stocks with low risk scores that highlights resilience while others concentrate on the latest headline momentum.
• Consider positioning ahead of electrification trends by reviewing a hand picked 16 top copper producer stocks aligned with long term infrastructure and power grid demand.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com